Editorial Atrial Fibrillation and Worse Outcomes in ST- Segment–Elevation Myocardial Infarction Is It All About Infarct Size, or Do We Need to Look Elsewhere? Promporn Suksaranjit, MD, MS; Brent D. Wilson, MD, PhD trial fibrillation (AF) is a common cardiac arrhythmia in analysis of data from a CMR substudy of the AIDA STEMI Apatients admitted to a hospital with myocardial infarction trial (Abciximab Intracoronary Versus Intravenous Drug (MI). In a large study looking at 106 780 patients, AF preva- Application in ST-Elevation Myocardial Infarction). They lence was 22%, with half of AF patients presenting with and used CMR data from this large, multicenter STEMI trial to half developing AF during their hospitalization for acute MI. examine the association between the presence of AF during With the use of implantable cardiac monitoring, AF incidence hospitalization and infarct characteristics by CMR and major was as high as 39% at 24 months in post-MI patients with left adverse cardiovascular events at 12 months after primary ventricular systolic dysfunction. The relationship between percutaneous coronary intervention (PPCI). A total of 786 AF and MI is complex and bidirectional, but it is clear that MI patients with STEMI who underwent CMR were included in 3,4
Circulation: Cardiovascular Imaging – Wolters Kluwer Health
Published: Feb 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
It’s easy to organize your research with our built-in tools.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud